Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009;189(189):203-41.
doi: 10.1007/978-3-540-79086-0_8.

Interferons and their use in persistent viral infections

Stéphane Chevaliez  1 , Jean-Michel Pawlotsky
Affiliations
Review

Interferons and their use in persistent viral infections

Stéphane Chevaliez et al. Handb Exp Pharmacol. 2009.

Abstract

In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN) by Isaacs and Lindenmann. Subsequently, the IFN-alpha gene was cloned, fully sequenced and IFN-alpha was produced in recombinant form. Recombinant IFN-alpha is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections.

PubMed Disclaimer

References

    1. (1997) National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26:2S–10S - PubMed
    1. (1999) EASL International Consensus Conference on hepatitis C. Paris, 26–27 February 1999. Consensus statement. J Hepatol 31 Suppl 1:3–8 - PubMed
    1. (2002) National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002-June 10–12, 2002. Hepatology 36:S3–S20 - PubMed
    1. Afdhal NH, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, Sherman KE, Jacobson I, Chao G, Knox S, Pietropaolo K, Brown N. Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior non-response to PEGIFN/RBV: week 24 results. J Hepatol. 2006;44(2):S19. doi: 10.1016/S0168-8278(06)80040-1. - DOI - PubMed
    1. Akarca US, Ersoz G, Gunsar F, Karasu Z, Saritas E, Yuce G, Batur Y. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther. 2004;9:325–334. - PubMed